Verified quality. Clean ingredients. Evidence-based protocols.
Live Last read · last published · next check
For the first time, a major U.S. medical center is testing whether a $2 antiparasitic drug can make immunotherapy work better against triple-negative breast cancer. Here's what we know — and why it matters.
A side-by-side comparison of the three most discussed antiparasitic compounds in experimental oncology — mechanisms, evidence quality, safety profiles, and protocols. Plus: your top 10 questions answered.
Everything you need to know about the protocol — dosing tiers, cycling schedules, essential blood tests, drug interactions, and red flags that require immediate medical attention.
A deep dive into the preclinical evidence — microtubule disruption, glucose starvation, p53 activation, and programmed cell death. What laboratory studies actually show, and what they don't.
A man diagnosed with terminal cancer went into complete remission. The internet credits a dog dewormer. But there's a critical fact most people don't mention.
